A Study of Intravenous PI3K Inhibitor Copanlisib in Combination with Standard Immunochemotherapy versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-4

About this Study

The purpose of this study is to evaluate the efficacy and safety of the study drug Copanlisib in combination with standard chemotherapy.

Sponsor Protocol ID:BAY 80-6946 / 17833
IRB Number:2017-0313
Actively Enrolling
Interventional
Phase 3
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Ability to understand and willingness to sign written informed consent.  
  • Patients must have relapsed.
  • Male or female patients ≥ 18 years of age. 
  • Life expectancy of at least 3 months. 
  • Availability of fresh tumor tissue and/or archival tumor tissue at Screening. 
  • Women of childbearing potential and men must agree to use effective contraception when sexually active. 
  • Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements conducted within 7 days of starting the study treatment.

Exclusion Criteria
  • Previous assignment to treatment during this study.
  • Patients permanently withdrawn from study participation will not be allowed to re-enter the study. 

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Lisa Freeman
Phone Number: 601-984-2541
Email: efreeman2@umc.edu
Principal Investigator:Elkins, Stephanie L, M.D.
How to participate in our Clinical Trials